FDA Approves SUBVENITE — OWP Pharmaceuticals, Inc.

OWP Pharmaceuticals, Inc. received FDA approval on September 16, 2025, for its generic version of the antiepileptic drug LAMOTRIGINE targeting epilepsy and bipolar disorder; the approval is expected to diversify the company’s revenu streams and intensify competition in the widely used oral brand name market.